CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference
CVRx (NASDAQ: CVRX) announced management will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CVRx (NASDAQ: CVRX) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026. The presentation begins at 3:45 p.m. PT and will be available via live webcast at the company's investor site. An archived recording will be posted after the live event and accessible at the same URL for a limited time.
This is a company investor presentation and not an earnings release or regulatory filing.
Details
News Market Reaction – CVRX
On Dec 22, the day this news came out, CVRX closed 2.62% below the previous close.
Data tracked by StockTitan Argus for the Dec 22 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference referenced in the announcement
- Presentation date
- Jan. 14, 2026
- Scheduled date of CVRx presentation at the conference
- Presentation time
- 3:45 p.m. PT
- Start time of the J.P. Morgan conference presentation
Historical Context
-
Management fireside chat at Piper Sandler healthcare conference webcast to investors.
-
Q3 2025 revenue growth, higher gross margin, narrowed net loss and updated guidance.
-
Management presentation at Jefferies Global Healthcare Conference with live webcast.
-
Announcement of Q3 2025 earnings release date and accompanying conference call details.
-
Q2 2025 revenue growth, favorable CMS payment proposals, but ongoing net loss reported.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
neuromodulation medical
cardiovascular diseases medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026. The Company's presentation will begin at 3:45 p.m. (PT).
A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.